Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5345639 | 1.00 | MAPT (0.36) | MAPTPIK3CDMEN1KMT2ACYP1A2 | |
| SCHEMBL13187932 | 0.97 | MAPT (0.35) | MAPTPIK3CDMEN1KMT2ACYP1A2 | |
| SCHEMBL22735634 | 0.97 | MAPT (0.35) | MAPTPIK3CDMEN1KMT2ACYP1A2 | |
| SCHEMBL3429386 | 0.91 | PIK3CD (0.31) | MAPTPIK3CDMEN1KMT2A | |
| SCHEMBL16838261 | 0.91 | HSD17B10 (0.35) | MAPTPIK3CDMEN1KMT2ACYP1A2 | |
| SCHEMBL22996250 | 0.91 | BLM (0.40) | MAPTPIK3CDMEN1KMT2AMAPK1 | |
| SCHEMBL16412265 | 0.91 | PIK3CD (0.31) | MAPTPIK3CDMEN1KMT2AMAPK1 | |
| SCHEMBL15965459 | 0.89 | TSHR (0.43) | MAPTPIK3CDMEN1KMT2AMAPK1 | |
| SCHEMBL12118043 | 0.87 | CYP1A2 (0.47) | MAPTPIK3CDMEN1KMT2ACYP1A2 | |
| SCHEMBL17489308 | 0.87 | TSHR (0.37) | MAPTMEN1KMT2ACYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048844-B1 | Preventing airway mucus production by administration of EGF-R antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-01 | — | — | US | claimed |
| WO-2009103719-A1 | SUBSTITUTED 4-(INDOL-3-YL)QUINAZOLINES AND USE AND PRODUCTION THEREOF | FREIE UNIVERSITÄT BERLIN (DE) | 2009-08-27 | — | — | WO | claimed |
| US-7358222-B2 | Preventing airway mucus production by administration of EGF-R antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-15 | — | — | US | claimed |
| EP-1846396-A2 | SUBSTITUTED 4-(INDOL-3-YL)QUINAZOLINES AND THEIR USE | Freie Universität Berlin (DE) | 2007-10-24 | — | — | EP | claimed |
| US-7132427-B2 | Quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | claimed |
| WO-2006084882-A2 | SUBSTITUTED 4-(INDOL-3-YL)QUINAZOLINES AND THEIR USE | FREIE UNIVERSITÄT BERLIN (DE) | 2006-08-17 | — | — | WO | claimed |
| EP-1408980-A4 | NOVEL QUINAZOLINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1408980-A2 | NOVEL QUINAZOLINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030100573-A1 | Novel quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | claimed |
| WO-2003000188-A2 | NOVEL QUINAZOLINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-0823900-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-12-27 | — | — | EP | claimed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | claimed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | claimed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | claimed |
| EP-4230264-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2026-01-28 | — | — | EP | disclosed |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-04-24 | — | — | US | disclosed |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2024-09-03 | — | — | US | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| EP-0356851-A2 | Process for the preparation of solutions of 1:2-chromium complex azo dyes | BASF Aktiengesellschaft (DE) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | MAPT 1334/4885PIK3CD 1975/4885MEN1 1301/4885 |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | MAPT 1334/4885PIK3CD 1975/4885MEN1 1301/4885 |
| US-20030100573-A1 | Novel quinazolines and uses thereof | UQCRB, NQO2, RAB7A | MAPT 3698/4885PIK3CD 4480/4885MEN1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.